An experimental Ebola drug healed all 18 monkeys infected with the deadly virus in a study, boosting hopes that the treatment might help fight the outbreak raging through west Africa — once more of it can be made.
The monkeys were given the drug, ZMapp, three to five days after they were infected with the virus and when most were showing symptoms. That is several days later than any other experimental Ebola treatment tested so far.
The drug also completely protected six other monkeys given a slightly different version of it three days after infection in a pilot test. These two studies are the first monkey tests ever done on ZMapp.
“The level of improvement was utterly beyond my honest expectation,” said one study leader, Gary Kobinger of the Public Health Agency of Canada in Winnipeg.
“For animal data, it’s extremely impressive,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which had a role in the work.
It is not known how well the drug would work in people, who can take up to 21 days to show symptoms and are not infected the way the lab monkeys were.
Several experts said it is not possible to estimate a window of opportunity for treating people, but that it was encouraging that the animals recovered when treated even after advanced disease developed.
The study was published online on Friday by the journal Nature.
ZMapp had never been tested in humans before two US aid workers who got Ebola while working in Africa were allowed to try it. The rest of the limited supply was given to five others.
There is no more ZMapp now, and once a new batch is ready, it still needs some basic tests before it can be tried again during the African outbreak, Fauci said.
“We do need to know what the proper dose is” in people and that it is safe, he said.
ZMapp is three antibodies that attach to cells infected with Ebola, helping the immune system kill them.
Of the seven people known to have been treated with ZMapp, two have died — a Liberian doctor and a Spanish priest. The priest received only one of three planned doses. The two Americans recovered, as have two Africans who received ZMapp in Liberia — a Congolese doctor and a Liberian physician’s assistant, who were to be released from a treatment center yesterday.
Doctors have said there is no way to know whether ZMapp made a difference or the survivors recovered on their own, as about 45 percent of people infected in this outbreak have.
ZMapp’s maker, Mapp Biopharmaceutical Inc, of San Diego, California, has said the small supply of the drug is now exhausted and that it will take several months to make more. The drug is grown in tobacco plants and was developed with US government support.
Kobinger said it takes about a month to make 20 to 40 doses at a Kentucky plant where the drug is being produced. Officials have said they are looking at other facilities and other ways to ramp up production, and Kobinger said there were plans for a clinical trial to test ZMapp in people early next year.
The monkey study involved scientists from the Canada health agency, Mapp Biopharmaceutical, the US National Institutes of Health and the US Army Medical Research Institute of Infectious Disease.
Eighteen monkeys were given lethal amounts of Ebola in a shot, then received three intravenous doses of ZMapp, given three days apart starting three to five days after they were infected.
All treated with ZMapp survived; three other infected monkeys who did not get the drug died within eight days.
Primates have been good stand-ins for people for many viral diseases, but how well they predict human responses to Ebola, “we just don’t know,” Duke University infectious disease specialist Cameron Wolfe said.
The study also “tells us nothing about side effects” people might have, he added.
Still, it was encouraging that even monkeys with severe symptoms got better, said Wolfe and Erica Ollmann Saphire, a Scripps Research Institute professor who has worked with some of the study leaders on antibodies to Ebola.
“The treatment window in humans needs to be established in a well-controlled trial” that also would explore the correct dose of ZMapp in people, Saphire said. “Given its tremendous efficacy in the ... primates, I don’t see how it couldn’t be helpful in people.”
CONFRONTATION: The water cannon attack was the second this month on the Philippine supply boat ‘Unaizah May 4,’ after an incident on March 5 The China Coast Guard yesterday morning blocked a Philippine supply vessel and damaged it with water cannons near a reef off the Southeast Asian country, the Philippines said. The Philippine military released video of what it said was a nearly hour-long attack off the Second Thomas Shoal (Renai Shoal, 仁愛暗沙) in the contested South China Sea, where Chinese ships have unleashed water cannons and collided with Philippine vessels in similar standoffs in the past few months. The China Coast Guard and other vessels “once again harassed, blocked, deployed water cannons, and executed dangerous maneuvers” against a routine rotation and resupply mission to
GLOBAL COMBAT AIR PROGRAM: The potential purchasers would be limited to the 15 nations with which Tokyo has signed defense partnership and equipment transfer deals Japan’s Cabinet yesterday approved a plan to sell future next-generation fighter jets that it is developing with the UK and Italy to other nations, in the latest move away from the country’s post-World War II pacifist principles. The contentious decision to allow international arms sales is expected to help secure Japan’s role in the joint fighter jet project, and is part of a move to build up the Japanese arms industry and bolster its role in global security. The Cabinet also endorsed a revision to Japan’s arms equipment and technology transfer guidelines to allow coproduced lethal weapons to be sold to nations
‘POLITICAL EARTHQUAKE’: Leo Varadkar said he was ‘no longer the best person’ to lead the nation and was stepping down for political, as well as personal, reasons Leo Varadkar on Wednesday announced that he was stepping down as Ireland’s prime minister and leader of the Fine Gael party in the governing coalition, citing “personal and political” reasons. Pundits called the surprise move, just 10 weeks before Ireland holds European Parliament and local elections, a “political earthquake.” A general election has to be held within a year. Irish Deputy Prime Minister Micheal Martin, leader of Fianna Fail, the main coalition partner, said Varadkar’s announcement was “unexpected,” but added that he expected the government to run its full term. An emotional Varadkar, who is in his second stint as prime minister and at
Thousands of devotees, some in a state of trance, gathered at a Buddhist temple on the outskirts of Bangkok renowned for sacred tattoos known as Sak Yant, paying their respects to a revered monk who mastered the practice and seeking purification. The gathering at Wat Bang Phra Buddhist temple is part of a Thai Wai Khru ritual in which devotees pay homage to Luang Phor Pern, the temple’s formal abbot, who died in 2002. He had a reputation for refining and popularizing the temple’s Sak Yant tattoo style. The idea that tattoos confer magical powers has existed in many parts of Asia